CoChat
Sign Up
Cited by 191Chemotherapy-induced organ toxicity mitigationAcute Kidney Injury ResearchChronic Kidney Disease and Diabetes

The predictive role of the biomarker kidney Molecule-1 (KIM-1) in acute kidney injury (AKI) cisplatin-induced nephrotoxicity

Open access
Tanase, Daniela Maria, Gosav, Evelina Maria, Radu, Smaranda, Costea, Claudia Florida, Ciocoiu, Manuela, Carauleanu, Alexandru, Lacatusu, Cristina Mihaela, Maranduca, Minela Aida +2 more·2019·International Journal of Molecular Sciences
DOI 10.3390/ijms20205238PMC PMC6834366
Open this paper in CoChat — free accountOpen PDF

Abstract

Acute kidney injury (AKI) following platinum-based chemotherapeutics is a frequently reported serious side-effect. However, there are no approved biomarkers that can properly identify proximal tubular injury while routine assessments such as serum creatinine lack sensitivity. Kidney-injury-molecule 1 (KIM-1) is showing promise in identifying cisplatin-induced renal injury both in vitro and in vivo studies. In this review, we focus on describing the mechanisms of renal tubular cells cisplatin-induced apoptosis, the associated inflammatory response and oxidative stress and the role of KIM-1 as a possible biomarker used to predict cisplatin associated AKI.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20205238

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • KIM-1 is a type-I membrane protein expressed by injured proximal-tubule cells, is induced after sublethal or lethal tubular injury, and is widely used as an early marker of acute kidney injury.

    “KIM-1, a type-I membrane protein expressed by injured proximal-tubule cells, is induced after sublethal or lethal tubular injury and is widely used as an early marker of acute kidney injury (Tanase et al., 2019).”

    From Material-dependent oxygen transport governs ischemia-reperfusion injury and drug response in a kidney microphysiological system (2026) · cites this paper as Tanase et al., 2019

    Section 2.1 describes KIM-1 as a proximal-tubule apical transmembrane protein found in proximal-tubule cells after injury, and sections 2.1 and 5 discuss its use as an early AKI biomarker. The copy does not specify that it is type-I or that it is induced after both sublethal and lethal injury. It also calls for further validation of its use in early diagnosis, so “widely used as an early marker” overstates the clinical-use claim. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • KIM-1 is a gene expressed in the proximal tubule that is induced by cellular injury or exposure to toxic substances.

    “KIM-1 is a gene expressed in the proximal tubule that is induced by cellular injury or exposure to toxic substances (Tanase et al., 2019).”

    From Material-dependent oxygen transport governs ischemia-reperfusion injury and drug response in a kidney microphysiological system (2026) · cites this paper as Tanase et al., 2019

    Section 2.1, “What Is KIM-1?” (page unavailable), describes KIM-1 as a proximal-tubule transmembrane protein whose levels are low normally and rise after injury, including toxic renal injury. It also says KIM-1 gene expression reflects ongoing damage. The source supports injury-associated expression but identifies KIM-1 itself as a protein, not a gene. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 162

  1. [2]Mehta R.L. Cerdá J. Burdmann E.A. Tonelli M. García-García G. Jha V. Susantitaphong P. Rocco M. Vanholder R. Sever M.S. International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): A human rights case for nephrology Lancet 2015 385 2616 2643 10.1016/S0140-6736(15)60126-X 25777661 · DOI
  2. [3]Faught L.N. Greff M.J. Rieder M. Koren G. Drug-induced acute kidney injury in children Br. J. Clin. Pharmacol. 2014 80 901 909 10.1111/bcp.12554 25395343 PMC4594733 · DOI
  3. [4]Sinert R. Peacock P.R. Acute kidney injury Tintinalli’s Emergency Medicine 8th ed. Tintinalli J.E. Stapczynski J.S. Ma A.J. Yealy D.M. Mecklern G.D. Cline D.M. McGraw-Hill New York, NY, USA 2016 575 581
  4. [5]Perazella M.A. Pharmacology behind common drug nephrotoxicities Clin. J. Am. Soc. Nephrol. 2018 13 1897 1908 10.2215/CJN.00150118 29622670 PMC6302342 · DOI
  5. [6]Dhodi D.K. Bhagat S.B. Pathak D. Patel S.B. Dinesh K. Drug-induced nephrotoxicity Int. J. Basic Clin. Pharmacol. 2014 3 591 597 10.5455/2319-2003.ijbcp20140826 · DOI
  6. [7]Loghman-Adham M. Kiu Weber C.I. Ciorciaro C. Mann J. Meier M. Detection and management of nephrotoxicity during drug development Expert Opin. Drug Saf. 2012 11 581 596 10.1517/14740338.2012.691964 22616935 · DOI
  7. [8]Bonventre J.V. Vaidya V.S. Schmouder R. Feig P. Dieterle F. Next-generation biomarkers for detecting kidney toxicity Nat. Biotechnol. 2010 28 436 440 10.1038/nbt0510-436 20458311 PMC3033582 · DOI
  8. [9]McCullough P.A. Bouchard J. Waikar S.S. Siew E.D. Endre Z.H. Goldstein S.L. Koyner J.L. Macedo E. Di Somma S. Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney Injury: Executive summary from the tenth consensus conference of the acute dialysis quality initiative (ADQI) ADQI Consensus on AKI Biomarkers and Cardiorenal Syndromes Karger Publishers Basel, Karger 2013 Volume 182 5 12 PMC3856225 23689652
  9. [10]Sari Z. Nephrotoxic Effects of Drugs Poisoning in the Modern World Ren. Fail. 2019 41 576 594 10.5772/intechopen.83644 · DOI
  10. [11]Paueksakon P. Fogo A.B. Druginduced nephropathies Histopathology 2017 70 94 108 10.1111/his.13064 27960238 · DOI
  11. [13]Murray P.T. Mehta R.L. Shaw A. Ronco C. Endre Z. Kellum J.A. Chawla L.S. Cruz D. Ince C. Okusa M.D. Potential use of biomarkers in acute kidney injury: Report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference Kidney Int. 2014 85 513 521 10.1038/ki.2013.374 24107851 PMC4198530 · DOI
  12. [14]Nagai J. Takano M. Molecular-targeted approaches to reduce renal accumulation of nephrotoxic drugs Expert Opin. Drug Metab. Toxicol. 2010 6 1125 1138 10.1517/17425255.2010.497140 20536274 · DOI
  13. [15]Kim S.Y. Moon A. Drug-Induced Nephrotoxicity and Its Biomarkers Biomol. Ther 2012 20 268 10.4062/biomolther.2012.20.3.268 24130922 PMC3794522 · DOI
  14. [16]Ozkok A. Edelstein C.L. Pathophysiology of cisplatin-induced acute kidney injury BioMed Res. Int. 2014 2014 967826 10.1155/2014/967826 25165721 PMC4140112 · DOI
  15. [17]Labaye J. Sarret D. Duvic C. Hérody M. Didelot F. Nédélec G. Noël L.H. Renal toxicity of oxaliplatin Nephrol. Dial. Transplant. 2005 20 1275 1276 10.1093/ndt/gfh826 15827046 · DOI
  16. [18]Ulusakarya A. Misra S. Haydar M. Habert H. Castagne V. Gumus Y. Delmas-Marsalet B. Machover D. Acute renal failure related to oxaliplatin-induced intravascular hemolysis Med. Oncol. 2010 27 1425 1426 10.1007/s12032-009-9263-3 19565364 · DOI
  17. [19]Yaghobi Joybari A. Sarbaz S. Azadeh P. Mirafsharieh S.A. Rahbari A. Farasatinasab M. Mokhtari M. Oxaliplatin-induced renal tubular vacuolization Ann. Pharmacother. 2014 48 796 800 10.1177/1060028014526160 24615628 · DOI
  18. [20]Isnard-Bagnis C. Launay-Vacher V. Karie S. Deray G. Anticancer drugs Clinical Nephrotoxins Renal Injury from Drug and Chemicals 3rd ed. De Broe M. Porter G. Bennett W. Deray G. Springer Scientific New York, NY, USA 2008
  19. [21]Feigelstock D. Thompson P. Mattoo P. Kaplan G.G. The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor J. Virol. 1998 72 6621 6628 9658108 PMC109848
  20. [22]Chiusolo A. Defazio R. Zanetti E. Mongillo M. Mori N. Cristofori P. Trevisan A. Kidney injury molecule-1 expression in rat proximal tubule after treatment with segment-specific nephrotoxicants: A tool for early screening of potential kidney toxicity Toxicol. Pathol. 2010 38 338 345 10.1177/0192623310362244 20305092 · DOI
  21. [23]Vaidya V.S. Ozer J.S. Dieterle F. Collings F.B. Ramirez V. Troth S. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies Nat. Biotechnol. 2010 28 478 485 10.1038/nbt.1623 20458318 PMC2885849 · DOI
  22. [24]Sasaki D. Yamada A. Umeno H. Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury Biomarkers 2011 16 553 566 10.3109/1354750X.2011.613123 21955166 · DOI
  23. [26]Dieterle F. Sistare F. Goodsaid M. Papaluca J.S. Ozer C.P. Webb W. Baer A. Senagore M.J. Walker E. Sultana S. Renal biomarker qualification submission: A dialog between the FDA-EMEA and Predictive Safety Testing Consortium Nat. Biotechnol. 2010 28 455 462 10.1038/nbt.1625 20458315 · DOI
  24. [27]Harpur E. Ennulat D. Hoffman D. Betton G. Gautier J.C. Riefke B. Bounous D. Schuster K. Beushausen S. Guffroy M. Nephrotoxicity Toxicol. Sci. 2011 122 235 252 10.1093/toxsci/kfr112 21593213 · DOI
  25. [28]Ichimura T. Bonventre J.V. Bailly V. Wei H. Hession C.A. Cate R.L. Sanicola M. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury J. Biol. Chem. 1998 273 4135 4142 10.1074/jbc.273.7.4135 9461608 · DOI
  26. [29]Hubank M. Schatz D.G. Identifying differences in mRNA expression by representational difference analysis of cDNA Nucl. Acids Res. 1994 22 5640 5648 10.1093/nar/22.25.5640 7838717 PMC310128 · DOI
  27. [30]Kuchroo V.K. Meyers J.H. Umetsu D.T. DeKruyff R.H. TIM family of genes in immunity and tolerance Adv. Immunol. 2006 91 227 249 16938542
  28. [31]Bonventre J.V. Kidney injury molecule-1 (KIM-1), “A urinary biomarker and much more” Nephrol. Dial. Transplant. 2009 24 3265 3268 10.1093/ndt/gfp010 19318357 · DOI
  29. [32]Van Timmeren M.M. van den Heuvel M.C. Bailly V. Bakker S.J. van Goor H. Stegeman C.A. Tubular kidney injury molecule-1 (KIM-1) in human renal disease J. Pathol. 2007 212 209 217 10.1002/path.2175 17471468 · DOI
  30. [33]Bailly V. Zhang Z. Meier W. Cate R. Sanicola M. Bonventre J.V. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration J. Biol. Chem. 2002 277 39739 39748 10.1074/jbc.M200562200 12138159 · DOI
  31. [34]Lim A.I. Tang S.C. Lai K.N. Leung J.C. Kidney injury molecule-1: More than just an injury marker of tubular epithelial cells? J. Cell. Physiol. 2013 228 917 924 10.1002/jcp.24267 23086807 · DOI
  32. [35]Visnagri A. Kandhare A.D. Bodhankar S.L. Renoprotectiveeffect of berberine via intonation on apoptosis andmitochondrial-dependent pathway in renal ischemia reperfusion-induced mutilation Ren. Fail. 2015 37 482 493 10.3109/0886022X.2014.996843 25598236 · DOI
  33. [36]Bonventre J.V. Yang L. Kidney injury molecule-1 Curr. Opin. Crit. Care 2010 16 556 561 10.1097/MCC.0b013e32834008d3 20930626 · DOI
  34. [37]Brooks C.R. Bonventre J.V. KIM-1/TIM-1 in proximal tubular cell immune response Oncotarget 2015 6 44059 10.18632/oncotarget.6623 26683362 PMC4792540 · DOI
  35. [38]Brooks C.R. Yeung M.Y. Brooks Y.S. Chen H. Ichimura T. Henderson J.M. Bonventre J.V. KIM-1-/TIM-1-mediated phagocytosis links ATG5-/ULK1-dependent clearance of apoptotic cells to antigen presentation EMBO J. 2015 34 2441 2464 10.15252/embj.201489838 26282792 PMC4601664 · DOI
  36. [39]Tsigou E. Psallida V. Demponeras C. Boutzouka E. Baltopoulos G. Role of new biomarkers: Functional andstructural damage Crit. Care Res. Pract. 2013 2013 361078 23476755 PMC3576734
  37. [40]Ichimura T. Brooks C.R. Bonventre J.V. Kim-1/ Tim-1 and immune cells: Shifting sands Kidney Int. 2012 81 809 811 10.1038/ki.2012.11 22499138 PMC3339439 · DOI
  38. [41]Gobe G.C. Coombes J.S. Fassett R.G. Endre Z.H. Biomarkers of drug-induced acute kidney injury in the adult Expert Opin. Drug Metab. Toxicol. 2015 11 1683 1694 10.1517/17425255.2015.1083011 26548752 · DOI
  39. [42]Kadioglu T. Uzunlulu M. Yigit Kaya S. Oguz A. Gonenli G. Isbilen B. Isman F.K. Urinary kidney injury molecule-1 levels as a marker of early kidney injury in hypertensive patients Minerva Urol. Nefrol. 2016 68 456 461 25923545
  40. [43]Sabbisetti V.S. Waikar S.S. Antoine D.J. Smiles A. Wang C. Ravisankar A. Ito K. Sharma S. Ramadesikan S. Lee M. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes J. Am. Soc. Nephrol. 2014 25 2177 2186 10.1681/ASN.2013070758 24904085 PMC4178434 · DOI
  41. [44]Perco P. Oberbauer R. Kidney injury molecule-1 as a biomarker of acute kidney injury in renal transplant recipients Nat. Clin. Pract. Nephrol. 2008 4 362 363 10.1038/ncpneph0828 18493238 · DOI
  42. [45]Medic B. Rovcanin B. Basta Jovanovic G. Radojevic-Skodric S. Prostran M. Kidney injury molecule-1 and cardiovascular diseases: From basic science to clinical practice BioMed Res. Int. 2015 2015 854070 10.1155/2015/854070 26697493 PMC4677159 · DOI
  43. [46]Shao X. Tian L. Xu W. Zhang Z. Wang C. Qi C. Ni Z. Mou S. Diagnostic Value of Urinary Kidney Injury Molecule 1 for Acute Kidney Injury: A Meta-Analysis PLoS ONE 2014 9 e84131 10.1371/journal.pone.0084131 24404151 PMC3880280 · DOI
  44. [47]Schulz C.A. Engström G. Nilsson J. Almgren P. Petkovic M. Christensson A. Nilsson P.M. Melander O. Melander M.O. Plasma kidney injury molecule-1 (p-KIM-1) levels and deterioration of kidney function over 16 years Nephrol. Dial. Transplant. 2019 1 9 10.1093/ndt/gfy382 30629206 PMC7049260 · DOI
  45. [48]John M. Arthur E.G. Hill J.L. Lewis E.C. Neely B.A. Janech M.G. Tumlin J.A. Chawla L.S. Shaw A.D. Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery Kidney Int. 2014 85 431 438 10.1038/ki.2013.333 24005224 PMC3880389 · DOI
  46. [49]Pinches M.D. Betts C.J. Bickerton S.J. Beattie L. Burdett L.D. Thomas H.T. Derbyshire N.A. Moores M. Price S.A. Evaluation of novel urinary renal biomarkers: Bio- logical variation and reference change values Toxicol. Pathol. 2012 40 541 549 10.1177/0192623311432436 22395790 · DOI
  47. [50]Tsuji S. Sugiura M. Tsutsumi S. Yamada H. Sex differences in the excretion levels of traditional and novel urinary biomarkers of nephrotoxicity in rats J. Toxicol. Sci. 2017 42 615 627 10.2131/jts.42.615 28904297 · DOI
  48. [51]Krawczeski C.D. Goldstein S.L. Woo J.G. Wang Y. Piyaphanee N. Ma Q. Bennett M. Devarajan P. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass J. Am. Coll. Cardiol. 2011 58 2301 2309 10.1016/j.jacc.2011.08.017 22093507 PMC3220882 · DOI
  49. [52]Sun I.O. Shin S.H. Cho A.Y. Yoon H.J. Chang M.Y. Lee K.Y. Clinical significance of NGAL and KIM-1 for acute kidney injury in patients with scrub typhus PLoS ONE 2017 12 e0175890 10.1371/journal.pone.0175890 28419138 PMC5395225 · DOI
  50. [53]Ornellas F.M. Ornellas D.S. Martini S.V. Bone Marrow–Derived Mononuclear Cell Therapy Accelerates Renal Ischemia- Reperfusion Injury Recovery by Apoptotic Related Molecules Cell. Physiol. Biochem. 2017 41 1736 1752 10.1159/000471866 28365681 · DOI
  51. [54]Szeto C.C. Kwan B.C. Lai K.B. Lai F.M. Chow K.M. Wang G. Luk C.C. Li P.K. Urinary expression of kidney injury markers in renal transplant recipients Clin. J. Am. Soc. Nephrol. 2010 5 2329 2337 10.2215/CJN.01910310 20671224 PMC2994096 · DOI
  52. [55]Nielsen S.E. Schjoedt K.J. Astrup A.S. Tarnow L. Lajer M. Hansen P.R. Parving H.H. Rossing P. Neutrophil gelatinase-associated lipocalin (ngal) and kidney injury molecule 1 (kim1) in patients with diabetic nephropathy: A cross-sectional study and the effects of lisinopril Diabet. Med. 2010 27 1144 1150 10.1111/j.1464-5491.2010.03083.x 20854382 · DOI
  53. [56]Zhang P.L. Mashni J.W. Sabbisetti V.S. Schworer C.M. Wilson G.D. Wolforth S.C. Kernen K.M. Seifman D.B. Amin B.M. Geddes T.J. Urine kidney injury molecule-1: A potential non-invasive biomarker for patients with renal cell carcinoma Int. Urol. Nephrol. 2014 46 379 388 10.1007/s11255-013-0522-z 23979814 PMC4066455 · DOI
  54. [57]Fuchs T.C. Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology AAPS J. 2011 13 615 631 10.1208/s12248-011-9301-x 21969220 PMC3231866 · DOI
  55. [58]Van Meer L. Moerland M. Cohen A.F. Burggraaf J. Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development Br. J. Clin. Pharmacol. 2014 77 947 957 10.1111/bcp.12282 24219059 PMC4093920 · DOI
  56. [59]Vokes E.E. Induction chemotherapy for head and neck cancer: Recent data Oncologist 2010 15 3 7 10.1634/theoncologist.2010-S3-03 21036882 · DOI
  57. [60]Ismaili N. Amzerin M. Flechon A. Chemotherapy in advanced bladder cancer: Current status and future J. Hematol. Oncol. 2011 4 35 10.1186/1756-8722-4-35 21906310 PMC3178536 · DOI
  58. [61]Moxley K.M. McMeekin D.S. Endometrial carcinoma: A review of chemotherapy, drug resistance, and the search for new agents Oncologist 2010 15 1026 1033 10.1634/theoncologist.2010-0087 20930101 PMC3227900 · DOI
  59. [62]Gronwald J. Byrski T. Lubinski J. Narod S.A. Cisplatin in breast cancer treatment in BRCA1 carriers Hered Cancer Clin. Pract. 2012 10 Suppl. 4 A17 10.1186/1897-4287-10-S4-A17 · DOI
  60. [63]Zarogoulidis K. Zarogoulidis P. Darwiche K. Boutsikou E. Machairiotis N. Tsakiridis K. Katsikogiannis N. Kougioumtzi I. Karapantzos I. Huang H. Treatment of non-small cell lung cancer (NSCLC) J. Thorac. Dis. 2013 5 S389 S396 10.3978/j.issn.2072-1439.2013.07.10 24102012 PMC3791496 · DOI
  61. [64]Chan B.A. Coward J.I.G. Chemotherapy advances in small-cell lung cancer J. Thorac. Dis. 2013 5 S565 S578 10.3978/j.issn.2072-1439.2013.07.43 24163749 PMC3804877 · DOI
  62. [65]Tucker B.M. Perazella M.A. Medications Nephrology Secrets 4th ed. Lerma E.V. Sparks M.A. Topf J. Elsevier Philadelphia, PA, USA 2018 78 83
  63. [66]Perazella M.A. Onco-nephrology: Renal toxicities of chemotherapeutic agents Clin. J. Am. Soc. Nephrol. 2012 7 1713 1721 10.2215/CJN.02780312 22879440 · DOI
  64. [67]Dos Santos N.A. Carvalho Rodrigues M.A. Martins N.M. dos Santos A.C. Cisplatininduced nephrotoxicity and targets of nephroprotection: An update Arch. Toxicol. 2012 86 1233 1250 10.1007/s00204-012-0821-7 22382776 · DOI
  65. [68]Miller R.P. Tadagavadi R.K. Ramesh G. Reeves W.B. Mechanisms of cisplatin nephrotoxicity Toxins 2010 2 2490 2518 10.3390/toxins2112490 22069563 PMC3153174 · DOI
  66. [69]Bolisetty S. Traylor A. Joseph R. Zarjou A. Agarwal A. Proximal tubule-targeted heme oxygenase-1 in cisplatin-induced acute kidney injury Am. J. Physiol. Ren. Physiol. 2016 310 F385 F394 10.1152/ajprenal.00335.2015 26672618 PMC4868370 · DOI
  67. [71]Atilano-Roque A. Wen X. Aleksunes L.M. Joy M.S. Nrf2 activators as potential modulators of injury in human kidney cell Toxicol. Rep. 2016 3 153 159 10.1016/j.toxrep.2016.01.006 28959534 PMC5615789 · DOI
  68. [72]Fliedl L. Wieser M. Manhart G. Gerstl M.P. Khan A. Grillari J. Grillari-Voglauer R. Controversial role of gamma-glutamyl transferase activity in cisplatin nephrotoxicity ALTEX 2014 31 269 278 10.14573/altex.1311152 24664430 · DOI
  69. [74]Ciarimboli G. Membrane transporters as mediators of cisplatin side effects Anticancer Res. 2014 34 547 550 10.6064/2012/473829 24403515 · DOI
  70. [75]Saito Y. Okamoto K. Kobayashi M. Narumi K. Furugen A. Yamada T. Iseki K. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration Life Sci. 2017 189 18 22 10.1016/j.lfs.2017.08.028 28864226 · DOI
  71. [76]Ciarimboli G. Membrane Transporters as Mediators of Cisplatin Effects and Side Effects Scientifica 2012 2012 473829 10.6064/2012/473829 24278698 PMC3820462 · DOI
  72. [77]Estrela G.R. Wasinski F. Felizardo R.J.F. Souza L.L. Câmara N.O.S. Bader M. Araujo R.C. MATE-1 modulation by kinin B1 receptor enhances cisplatin efflux from renal cells Mol. Cell. Biochem. 2017 428 101 10.1007/s11010-016-2920-x 28161805 · DOI
  73. [78]Harrach S. Ciarimboli G. Role of transporters in the distribution of platinum-based drugs Front. Pharmacol. 2015 6 85 10.3389/fphar.2015.00085 25964760 PMC4408848 · DOI
  74. [79]Zhu N. Pabla C. Tang C. He L. Dong Z. DNA damage response in cisplatin-induced nephrotoxicity Arch. Toxicol. 2015 89 2197 2205 10.1007/s00204-015-1633-3 26564230 PMC4734632 · DOI
  75. [80]Manohar S. Leung N. Cisplatin nephrotoxicity: A review of the literature J. Nephrol. 2018 31 15 25 10.1007/s40620-017-0392-z 28382507 · DOI
  76. [81]Xu Y. Ma H. Shao J. Wu J. Zhou L. Zhang Z. Wang Y. Huang Z. Ren J. Liu S. A role for Tubular Necroptosis in Cisplatin-Induced AKI JASN 2015 26 2647 2658 10.1681/ASN.2014080741 25788533 PMC4625668 · DOI
  77. [82]Basu A. Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage J. Nucl. Acids 2010 2010 201367 10.4061/2010/201367 PMC2929606 20811617 · DOI
  78. [83]Sharp C.N. Doll M.A. Dupre T.V. Shah P.P. Subathra M. Siow D. Arteel G.E. Megyesi J. Beverly L.J. Siskind L.J. Repeated administration of low-dose cisplatin in mice induces fibrosis Am. J. Physiol. Renal. Physiol. 2016 310 F560 F568 10.1152/ajprenal.00512.2015 26739893 PMC4796272 · DOI
  79. [84]Vaseva A.V. Moll U.M. The mitochondrial p53 pathway Biochim. Biophys. Acta 2009 1787 414 420 10.1016/j.bbabio.2008.10.005 19007744 PMC2819081 · DOI
  80. [85]Siskind L.J. Repeated administration of low-dose cisplatin in mice induces fibrosis Am. J. Physiol. Ren. Physiol. 2016 310 F560 F568 10.1152/ajprenal.00512.2015 PMC4796272 26739893 · DOI
  81. [86]Bhatt K. Zhou L. Mi Q.S. Huang S. She J.X. Dong Z. MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival Mol. Med. 2010 16 409 416 10.2119/molmed.2010.00002 20386864 PMC2935954 · DOI
  82. [87]Nakagawa T. Kakizoe Y. Iwata Y. Miyasato Y. Mizumoto T. Adachi M. Izumi Y. Kuwabara T. Suenaga N. Narita Y. Doxycycline attenuates cisplatin-induced acute kidney injury through pleiotropic e_ects Am. J. Physiol. Ren. Physiol. 2018 315 F1347 F1357 10.1152/ajprenal.00648.2017 PMC6293283 30043627 · DOI
  83. [88]Watanabe M. Oe Y. Sato E. Sekimoto A. Sato H. Ito S. Takahashi N. Protease-activated receptor 2 exacerbates cisplatin-induced nephrotoxicity Am. J. Physiol. Ren. Physiol. 2019 316 F654 F659 10.1152/ajprenal.00489.2018 30672316 · DOI
  84. [89]Soni H. Matthews A.T. Pallikkuth S. Gangaraju R. Adebiyi A. Gamma-secretase inhibitor DAPT mitigates cisplatin-induced acute kidney injury by suppressing Notch1 signaling J. Cell. Mol. Med. 2019 23 260 270 10.1111/jcmm.13926 30407728 PMC6307805 · DOI
  85. [90]Zhang W. Hou J. Yan X. Leng J. Li R. Zhang J. Xing J. Chen C. Wang Z. Li W. Platycodon grandiflorum Saponins Ameliorate Cisplatin-Induced Acute Nephrotoxicity through the NF-kappaB-Mediated Inflammation and PI3K/Akt/Apoptosis Signaling Pathways Nutrients 2018 10 1328 10.3390/nu10091328 30235825 PMC6164643 · DOI
  86. [91]Sen Z. Jie M. Jingzhi Y. Dongjie W. Dongming Z. Xiaoguang C. Total Coumarins from Hydrangea paniculata Protect against Cisplatin-Induced Acute Kidney Damage in Mice by Suppressing Renal Inflammation and Apoptosis Evid. Based Complement. Altern. Med. 2017 2017 5350161 10.1155/2017/5350161 28367225 PMC5358452 · DOI
  87. [92]Parameswaran N. Patial S. Tumor necrosis factor-alpha signaling in macrophages Crit. Rev. Eukaryot. Gene Expr. 2010 20 87 103 10.1615/CritRevEukarGeneExpr.v20.i2.10 21133840 PMC3066460 · DOI
  88. [93]Dupre T.V. Doll M.A. Shah P.P. Sharp C.N. Kiefer A. Scherzer M.T. Saurabh K. Saforo D. Siow D. Casson L. Suramin protects from cisplatin-induced acute kidney injury Am. J. Physiol. Ren. Physiol. 2016 310 F248 F258 10.1152/ajprenal.00433.2015 PMC4877945 26661653 · DOI
  89. [94]Dupre T.V. Doll M.A. Shah P.P. Sharp C.N. Siow D. Megyesi J. Shayman J. Bielawska A. Bielawski J. Beverly L.J. Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury J. Lipid Res. 2017 58 1439 1452 10.1194/jlr.M076745 28490444 PMC5496040 · DOI
  90. [95]Kong D. Zhuo L. Gao C. Shi S. Wang N. Huang Z. Li W. Hao L. Erythropoieti protects against cisplatin-induced nephrotoxicity by attenuating endoplasmic reticulum stress-induced apoptosis J. Nephrol. 2013 26 219 227 10.5301/jn.5000177 22711436 · DOI
  91. [96]Mapuskar K.A. Wen H. Holanda D.G. Rastogi P. Steinbach E. Han R. Coleman M.C. Attanasio M. Riley D.P. Spitz D.R. Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease Redox Biol. 2019 20 98 106 10.1016/j.redox.2018.09.020 30296702 PMC6174865 · DOI
  92. [97]Tang J. Shi Y. Liu N. Xu L. Zang X. Li P. Zhang J. Zheng X. Qiu A. Zhuang S. Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury Clin. Sci. 2018 132 339 359 10.1042/CS20171417 29358506 · DOI
  93. [98]Perico L. Morigi M. Rota C. Breno M. Mele C. Noris M. Introna M. Capelli C. Longaretti L. Rottoli D. Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function Nat. Commun. 2017 8 983 10.1038/s41467-017-00937-2 29042548 PMC5754365 · DOI
  94. [99]Volarevic V. Djokovic B. Gazdic M.J. Harrell R. Fellabaum C. Djono V. Arsenijevic N. Molecular mechanisms of cisplatin-induced nephrotoxicity: A balance on the knife edge between renoprotection and tumor toxicity J. Biomed. Sci. 2019 26 25 10.1186/s12929-019-0518-9 30866950 PMC6417243 · DOI
  95. [100]Hosohata K. Role of oxidative stress in drug-induced kidney injury Int. J. Mol. Sci. 2016 17 1826 10.3390/ijms17111826 27809280 PMC5133827 · DOI
  96. [101]Peres L.A. da Cunha A.D. Jr. Acute nephrotoxicity of cisplatin: Molecular mechanisms J. Bras. Nefrol. 2013 35 332 340 10.5935/0101-2800.20130052 24402113 · DOI
  97. [102]Ibrahim A. Al-Hizab F.A. Abushouk A.I. Abdel-Daim M.M. Nephroprotective E_ects of Benzyl Isothiocyanate and Resveratrol Against Cisplatin-Induced Oxidative Stress and Inflammation Front. Pharmacol. 2018 9 1268 10.3389/fphar.2018.01268 30524274 PMC6258716 · DOI
  98. [103]Qi Z. Li Z. Li W. Liu Y. Wang C. Lin H. Liu J. Li P. Pseudoginsengenin DQ Exhibits Therapeutic E_ects in Cisplatin-Induced Acute Kidney Injury via Sirt1/NF-kappaB and Caspase Signaling Pathway without Compromising Its Antitumor Activity in Mice Molecules 2018 23 3038 10.3390/molecules23113038 30469321 PMC6278544 · DOI
  99. [104]Wang Z. Li Y.F. Han X.Y. Sun Y.S. Zhang L.X. Liu W. Liu X.X. Li W. Liu Y.Y. Kidney Protection E_ect of Ginsenoside Re and Its Underlying Mechanisms on Cisplatin-Induced Kidney Injury Cell. Physiol. Biochem. 2018 48 2219 2229 10.1159/000492562 30110677 · DOI
  100. [105]Oh G.S. Kim H.J. Shen A. Lee S.B. Yang S.H. Shim H. Young Cho E. Beom Kwon K. Hwan Kwak T. So H.S. New Therapeutic Concept of NAD Redox Balance for Cisplatin Nephrotoxicity BioMed Res. Int. 2016 2016 4048390 10.1155/2016/4048390 26881219 PMC4736397 · DOI
  101. [106]Srivastava S. Sinha D. Saha P.P. Marthala H. D’Silva P. Magmas functions as a ROS regulator and provides cytoprotection against oxidative stress-mediated damages Cell Death Dis. 2014 5 e1394 10.1038/cddis.2014.355 25165880 PMC4454327 · DOI
  102. [107]Tang C. Dong Z. Mitochondria in Kidney Injury: When the Power Plant Fails J. Am. Soc. Nephrol. 2016 27 1869 1872 10.1681/ASN.2015111277 26744487 PMC4926990 · DOI
  103. [108]Hall A.M. Schuh C.D. Mitochondria as therapeutic targets in acute kidney injury Curr. Opin. Nephrol. Hypertens. 2016 25 355 362 10.1097/MNH.0000000000000228 27166518 · DOI
  104. [109]Oh G.S. Kim H.J. Choi J.H. Shen A. Choe S.K. Karna A. Lee S.H. Jo H.J. Yang S.H. Kwak T.H. Pharmacological activation of NQO1 increases NAD(+) levels and attenuates cisplatin-mediated acute kidney injury in mice Kidney Int. 2014 85 547 560 10.1038/ki.2013.330 24025646 PMC3944666 · DOI
  105. [110]Perse M. Veceric-Haler Z. Cisplatin-Induced Rodent Model of Kidney Injury: Characteristics and Challenges BioMed Res. Int. 2018 2018 1462802 10.1155/2018/1462802 30276200 PMC6157122 · DOI
  106. [111]Zhang B. Ramesh G. Norbury C.C. Reeves W.B. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells Kidney Int. 2007 72 37 44 10.1038/sj.ki.5002242 17396112 · DOI
  107. [112]Mukhopadhyay P. Horváth B. Kechrid M. Tanchian G. Rajesh M. Naura A.S. Boulares A.H. Pacher P. Poly (ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury Free Radic. Biol. Med. 2011 51 1774 1788 10.1016/j.freeradbiomed.2011.08.006 21884784 PMC3207278 · DOI
  108. [113]Inoue T. M1 macrophage triggered by Mincle leads to a deterioration of acute kidney injury Kidney Int. 2017 91 526 529 10.1016/j.kint.2016.11.026 28202166 · DOI
  109. [114]Summers S.A. Chan J. Gan P.Y. Dewage L. Nozaki Y. Steinmetz O.M. Nikolic-Paterson D.J. Kitching A.R. Holdsworth S.R. Mast cells mediate acute kidney injury through the production of TNF J. Am. Soc. Nephrol. 2011 22 2226 2236 10.1681/ASN.2011020182 22021718 PMC3279934 · DOI
  110. [115]Soni H. Kaminski D. Gangaraju R. Adebiyi A. Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding Ren. Fail. 2018 40 314 322 10.1080/0886022X.2018.1456938 29619879 PMC6014303 · DOI
  111. [116]Yang L. Brooks C.R. Xiao S. Sabbisetti V. Yeung M.Y. Hsiao L.L. Ichimura T. Kuchroo V. Bonventre J.V. KIM-1-mediated phagocytosis reduces acute injury to the kidney J. Clin. Investig. 2015 125 1620 1636 10.1172/JCI75417 25751064 PMC4396492 · DOI
  112. [117]Endre Z.H. Recovery from Acute Kidney Injury: The Role of Biomarkers Nephron Clin. Pract. 2014 127 101 105 10.1159/000363678 25343830 · DOI
  113. [118]Liu X. Guan Y. Xu S. Li Q. Sun Y. Han R. Jiang C. Early Predictors of Acute Kidney Injury: A Narrative Review Kidney Blood Press. Res. 2016 41 680 700 10.1159/000447937 27676272 · DOI
  114. [119]Rizo-Topete L.M. Rosner M.H. Ronco C. Acute Kidney Injury Risk Assessment and the Nephrology Rapid Response Team, Role of the Nephrologist in Multidisciplinary Management of AKI Blood Purif. 2017 43 82 88 10.1159/000452402 27915329 · DOI
  115. [120]Nozaki Y. Kinoshita K. Hino S. Yano T. Niki K. Hirooka Y. Kishimoto K. Funauchi M. Matsumura I. Signaling Rho-kinase mediates inflammation and apoptosis in T cells and renal tubules in cisplatin nephrotoxicity Am. J. Physiol. Ren. Physiol. 2015 308 F899 F909 10.1152/ajprenal.00362.2014 25651561 · DOI
  116. [121]Sinha V. Vence L.M. Salahudeen A.K. Urinary tubular proteinbased biomarkers in the rodent model of cisplatin nephrotoxicity: A comparative analysis of serum creatinine, renal histology, and urinary KIM-1, NGAL, and NAG in the initiation, maintenance, and recovery phases of acute kidney injury J. Investig. Med. 2013 61 564 568 23360846
  117. [122]Shinke H. Masuda S. Togashi Y. Ikemi Y. Ozawa A. Sato T. Kim Y.H. Mishima M. Ichimura T. Bonventre J.V. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients Cancer Chemother. Pharmacol. 2015 76 989 996 10.1007/s00280-015-2880-y 26407820 PMC4624288 · DOI
  118. [123]Faig J. Haughton M. Taylor R.C. D’Agostino R.B. Jr. Whelen M.J. Rodriguez K.A. Bonomi M. Murea M. Porosnicu M. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck Cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy Am. J. Clin. Oncol. 2018 41 432 440 10.1097/COC.0000000000000301 27281266 PMC5145782 · DOI
  119. [124]Prasaja Y. Sutandyo N. Andrajati R. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia Asian Pac. J. Cancer Prev. 2015 16 1117 1122 10.7314/APJCP.2015.16.3.1117 25735341 · DOI
  120. [125]Tekce B.K. Uyeturk U. Tekce H. Uyeturk U. Aktas G. Akkaya A. Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage? Ann. Clin. Biochem. 2015 52 88 94 10.1177/0004563214528312 24670880 · DOI
  121. [126]Abdelsalam M. Elmorsy E. Abdelwahab H. Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity BMC Nephrol. 2018 19 219 10.1186/s12882-018-1022-2 30180818 PMC6123931 · DOI
  122. [127]Oh S.M. Park G. Lee S.H. Seo C.S. Shin H.K. Oh D.S. Assessing the recovery from prerenal and renal acute kidney injury after treatment with single herbal medicine via activity of the biomarkers HMGB1, NGAL and KIM-1 in kidney proximal tubular cells treated by cisplatin with different doses and exposure times BMC Complement. Altern. Med. 2017 17 544 10.1186/s12906-017-2055-y 29258482 PMC5738030 · DOI
  123. [128]McMahon K.R. Rod Rassekh S. Schultz K.R. Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study Can. J. Kidney Health Dis. 2017 4 1 13 10.1177/2054358117690338 PMC5317038 28270931 · DOI
  124. [129]Salem N. Helmi N. Assaf N. Renoprotective Effect of Platelet-Rich Plasma on Cisplatin-Induced Nephrotoxicity in Rats Oxid. Med. Cell. Longev. 2018 2018 9658230 10.1155/2018/9658230 30116500 PMC6079401 · DOI
  125. [130]Jun D.Y. Kim S.Y. Na J.C. Lee H.H. Kim J. Yoon Y.E. Hong S.J. Han W.K. Tubular organotypic culture model of human kidney PLoS ONE 2018 13 e0206447 10.1371/journal.pone.0206447 30379927 PMC6209336 · DOI
  126. [131]Huang J.X. Kaeslin G. Ranall M.V. Evaluation of biomarkers for in vitro prediction of druginduced nephrotoxicity: Comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells Pharmacol. Res. Perspect. 2015 3 e00148 10.1002/prp2.148 26171227 PMC4492764 · DOI
  127. [132]Wang X. Grunz-Borgmann E.A. Parrish A.R. Loss of _(E)-Catenin Potentiates Cisplatin-Induced Nephrotoxicity via Increasing Apoptosis in Renal Tubular Epithelial Cells Toxicol. Sci. 2014 141 254 262 10.1093/toxsci/kfu130 24973089 PMC4271126 · DOI
  128. [133]Gardiner L. Akintola A. Chen G. Catania J.M. Vaidya V. Burghardt R.C. Bonventre J.V. Trzeciakowski J. Parrish A.R. Structural equation modeling highlights the potential of Kim-1 as a biomarker for chronic kidney disease Am. J. Nephrol. 2012 35 152 163 10.1159/000335579 22269876 PMC3326283 · DOI
  129. [134]Timothy J. Piantaa B. John W. Succar P.L. Chin M. Davidson T. Buckley N.A. Mohamed F. Endre Z.H. Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy Kidney Blood Press. Res. 2017 42 62 75 10.1159/000469715 28315878 · DOI
  130. [135]Meng H. Fu G. Shen J. Shen K. Xu Z. Wang Y. Jin B. Pan H. Ameliorative Effect of Daidzein on Cisplatin-Induced Nephrotoxicity in Mice via Modulation of Inflammation, Oxidative Stress, and Cell Death Oxid. Med. Cell. Longev. 2017 2017 3140680 10.1155/2017/3140680 28831294 PMC5558675 · DOI
  131. [136]McDuffie J.E. Chen Y. Ma J.Y. Lee K.M. Lynch D.M. Hamlin L. Nguyen M. Rizzolio M. Soneed M. Snooka S. Cisplatin nephrotoxicity in male beagle dogs: Next-generation protein kidney safety biomarker tissue expression and related changes in urine Toxicol. Res. 2016 5 1202 10.1039/C5TX00497G PMC6062370 30090426 · DOI
  132. [137]Nishihara K. Masuda S. Shinke H. Ozawa A. Ichimura T. Yonezawa A. Nakagawa S. Inui K. Bonventre J.V. Matsubara K. Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity Biochem. Pharmacol. 2013 15 570 582 10.1016/j.bcp.2012.12.019 PMC4077184 23291264 · DOI
  133. [138]DesRochers T.M. Suter L. Roth A. Kaplan D.L. Bioengineered 3D Human Kidney Tissue, a Platform for the Determination of Nephrotoxicity PLoS ONE 2013 8 e59219 10.1371/annotation/fb32f1b8-7397-40be-bbf9-b80e67763043 23516613 PMC3597621 · DOI
  134. [139]Rysz J. Gluba-Brzózka A. Franczyk B. Jabłonowski Z. Ciałkowska-Rysz A. Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome Int. J. Mol. Sci. 2017 18 1702 10.3390/ijms18081702 28777303 PMC5578092 · DOI
  135. [140]Vinken P. Starckx S. Barale-Thomas E. Looszova A. Sonee M. Goeminne N. Vermissen L. Buyens K. Lampo A. Tissue Kim-1and urinary clusterin as early indicators of cisplatin-induced acute kidney injury in rats Toxicol. Pathol. 2012 40 1049 1062 10.1177/0192623312444765 22581811 · DOI
  136. [141]Hany H. Araba B. Samir A. Salamaa C. Maghrabi I.A. Camel Milk Ameliorates 5-Fluorouracil- Induced Renal Injury in Rats: Targeting MAPKs, NF-κB and PI3K/Akt/eNOS Pathways Cell. Physiol. Biochem. 2018 46 1628 1642 10.1159/000489210 29694984 · DOI
  137. [142]Abdelrahman A.M. Al Suleimani Y. Shalaby A. Ashique M. Manoj P. Al-Saadi H. Ali B.H. Effect of levosimendan, a calcium sensitizer, on cisplatin-induced nephrotoxicity in rats Toxicol. Rep. 2019 6 232 238 10.1016/j.toxrep.2019.02.006 30886824 PMC6402298 · DOI
  138. [143]Sharp C.N. Siskind L.J. Developing better mouse models to study cisplatin-induced kidney injury Am. J. Physiol. Ren. Physiol. 2017 313 F835 F841 10.1152/ajprenal.00285.2017 PMC5668582 28724610 · DOI
  139. [144]Ali B.H. Abdelrahman A.M. Al-Salam S. Sudhadevi M. AlMahruqi A.S. Al-Husseni I.S. Beegam S. Dhanasekaran S. Nemmar A. Al-Moundhri M. The effect of sildenafil on cisplatin nephrotoxicity in rats Basic Clin. Pharmacol. Toxicol. 2011 109 300 308 10.1111/j.1742-7843.2011.00724.x 21575139 · DOI
  140. [145]Al Suleimani Y.M. Abdelrahman A.M. AlMahruqi A.S. Alhseini I.S. Tageldin M.H. Mansour M.E. Ali B.H. Interaction of nimesulide, a cyclooxygenase- 2 inhibitor, with cisplatin in normotensive and spontaneously hypertensive rats Food Chem. Toxicol. 2010 48 139 144 10.1016/j.fct.2009.09.030 19786061 · DOI
  141. [146]Khames A. Khalaf M.M. Gad A.M. Abd El-Raouf O.M. Kandeil M.A. Nicorandil combats doxorubicin-induced nephrotoxicity via amendment of TLR4/P38 MAPK/NFκ-B signaling pathway Chem. Biol. Interact. 2019 311 108777 10.1016/j.cbi.2019.108777 31376360 · DOI
  142. [147]Khan T.H. Ganaie M.A. Alharthy K.M. Madkhali H. Jan B.L. Sheikh I.A. Naringenin prevents doxorubicin-induced toxicity in kidney tissues by regulating the oxidative and inflammatory insult in Wistar rats Arch. Physiol. Biochem. 2018 8 1 8 10.1080/13813455.2018.1529799 30406686 · DOI
  143. [148]Rashid S. Ali N. Nafees S. Hasan S.K. Sultana S. Mitigation of 5-Fluorouracil induced renal toxicity by chrysin via targeting oxidative stress and apoptosis in wistar rats Food Chem. Toxicol. 2014 66 185 193 10.1016/j.fct.2014.01.026 24486618 · DOI
  144. [149]Vaidya V.S. Ford G.M. Waikar S.S. Wang Y. Clement M.B. Ramirez V. Glaab W.E. Troth S.P. Bonventre J.V. A rapid urine test for early detection of kidney injury Kidney Int. 2009 76 108 114 10.1038/ki.2009.96 19387469 PMC2737345 · DOI
  145. [150]Sabbisetti V.S. Ito K. Wang C. Mefferd S.C. Bonventre J.V. Novel Assays for Detection of Urinary KIM-1 in Mouse Models of Kidney Injury Toxicol. Sci. 2013 131 13 25 10.1093/toxsci/kfs268 23019274 PMC3621351 · DOI
  146. [151]Ragab D. Abdallah D.M. El-Abhar H.S. Cilostazol Renoprotective Effect: Modulation of PPAR-c, NGAL, KIM-1 and IL-18 Underlies Its Novel Effect in a Model of Ischemia-Reperfusion PLoS ONE 2014 9 e95313 10.1371/journal.pone.0095313 24816434 PMC4015937 · DOI
  147. [152]Xu J. Sun L. Sun W. Tian J. Guo H. Targeted Silencing of Kim-1 Inhibits the Growth of Clear Cell Renal Cell Carcinoma Cell Line 786-0 In Vitro and in Vivo Oncol. Res. 2018 26 997 1003 10.3727/096504017X15140544654946 29295730 PMC7844727 · DOI
  148. [153]Hayati F. Hossainzadeh M. Shayanpour S. Abedi-Gheshlaghi Z. Beladi Mousavi S.S. Prevention of cisplatin nephrotoxicity J. Nephropharmacol. 2016 5 57 60 28197500 PMC5297508
  149. [154]Crona D.J. Faso A. Nishijima T.F. McGraw K.A. Galsky M.D. Milowsky M.I. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity Oncologist 2017 22 609 619 10.1634/theoncologist.2016-0319 28438887 PMC5423518 · DOI
  150. [155]Rafieian-Kopaei M. Baradaran A. Rafieian M. Plants antioxidants: From laboratory to clinic J. Nephropathol. 2013 2 152 153 10.5812/nephropathol.12116 24475444 PMC3891140 · DOI
  151. [157]Abdel-Daim M.M. Abushouk A.I. Donia T. Alarifi S. Alkahtani S. Aleya L. Bungau S.G. The nephroprotective effects of allicin and ascorbic acid against cisplatin-induced toxicity in rats Environ. Sci. Pollut. Res. 2019 26 13502 10.1007/s11356-019-04780-4 30911969 · DOI
  152. [158]Ridzuan N.R. Rashid N.A. Othman F. Budin S.B. Hussan F. Teoh S.L. Protective Role of Natural Products in Cisplatin-Induced Nephrotoxicity Mini Rev. Med. Chem. 2019 19 1134 10.2174/1389557519666190320124438 30894108 · DOI
  153. [159]Cascella M. Palma G. Barbieri A. Bimonte S. Amruthraj N.J. Muzio M.R. Del Vecchio V. Rea D. Falco M. Luciano A. Role of Nigella sativa and Its Constituent Thymoquinone on Chemotherapy-Induced Nephrotoxicity: Evidences from Experimental Animal Studies Nutrients 2017 9 625 10.3390/nu9060625 28629150 PMC5490604 · DOI
  154. [160]Hosseinian S. Khajavi Rad A. Hadjzadeh M.A.R. Mohamadian Roshan N. Havakhah S. Shafiee S. The protective effect of Nigella sativa against cisplatin-induced nephrotoxicity in rats Avicenna J. Phytomed. 2016 6 44 54 27247921 PMC4884217
  155. [161]Santos N.A. Bezerra C.S. Martins N.M. Curti C. Bianchi M.L. Santos A.C. Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria Cancer Chemother. Pharmacol. 2008 61 145 155 10.1007/s00280-007-0459-y 17396264 · DOI
  156. [162]Lynch E.D. Gu R. Pierce C. Kil J. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen Hear. Res. 2005 201 81 89 10.1016/j.heares.2004.08.002 15721563 · DOI
  157. [163]Hensley M.L. Hagerty K.L. Kewalramani T. Green D.M. Meropol N.J. Wasserman T.H. Cohen G.I. Emami B. Gradishar W.J. Mitchell R.B. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants J. Clin. Oncol. 2009 27 127 145 10.1200/JCO.2008.17.2627 19018081 · DOI
  158. [164]Mousavi S.S. Zadeh M.H. Shahbazian H. Khanzadeh A. Hayati F. Ghorbani A. Golzari K. Valavi E. Motemednia F. Mousavi M.B. The protective effect of theophylline in cisplatin nephrotoxicity Saudi J. Kidney Dis. Transpl. 2014 25 333 337 10.4103/1319-2442.128528 24626000 · DOI
  159. [165]Katsuda H. Yamashita M. Katsura H. Yu J. Waki Y. Nagata N. Miyamoto K. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumoractivity Biol. Pharm. Bull. 2010 33 1867 1871 10.1248/bpb.33.1867 21048313 · DOI
  160. [166]Mercantepe F. Mercantepe T. Topcu A. Ylmaz A. Tumkaya L. Protective effects of amifostine, curcumin, and melatonin against cisplatin- induced acute kidney injury Naunyn-Schmiedeberg’s Arch. Pharmacol. 2018 391 915 10.1007/s00210-018-1514-4 29860655 · DOI
  161. [167]Wei L. Chen W. Zou Y. Huang H. Pan B. Jin S. Huang R. Nie S. Kong G. AMP-activated protein kinase regulates autophagic protection against cisplatin-induced tissue injury in the kidney Genet. Mol. Res. 2015 14 12006 12015 10.4238/2015.October.5.13 26505347 · DOI
  162. [168]Gaião S.M. Paiva J.A.O.D.C. Biomarkers of renal recovery after acute kidney injury Rev. Bras. Ter. Intensiva 2017 29 373 381 10.5935/0103-507X.20170051 29044306 PMC5632981 · DOI

Cited by

Sorted by citations

Authors
Tanase, D. M., Gosav, E. M., Radu, S., Costea, C. F., Ciocoiu, M., Carauleanu, A., Lacatusu, C. M., Maranduca, M. A., Floria, M., & Rezus, C.
Affiliations
  • Department of Internal Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700111 Iasi, Romania
  • Grigore T. Popa University of Medicine and Pharmacy (RO)
  • Department of Obstetrics and Gynecology, “Grigore T. Popa” University of Medicine and Pharmacy, 700111 Iasi, Romania
  • Unit of Diabetes, Nutrition and Metabolic Diseases, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
  • Internal Medicine Clinic, “Sf. Spiridon” County Clinical Emergency Hospital Iasi, 700115 Iasi, Romania
Corresponding author
  • Gosav, Evelina Maria
  • Floria, Mariana
ORCID
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-10-22
Volume
20
Issue
20
Pages
5238
ISSN
1422-0067 (ISSN-L)
DOI
10.3390/ijms20205238
PMC
PMC6834366
OpenAlex
W2981879786
Cited by
191
References
1
Citations by year
2026: 29 · 2025: 31 · 2024: 35 · 2023: 24 · 2022: 34 · 2021: 22 · 2020: 16
FWCI
2.68
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Chemotherapy-induced organ toxicity mitigation
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
KIM-1, acute kidney injury, cisplatin nephrotoxicity, biomarkers, proximal tubule injury, apoptosis, oxidative stress, inflammation, platinum-based chemotherapy, predictive biomarkers
MeSH terms
Hepatitis A Virus Cellular Receptor 1, Animals, Antineoplastic Agents, Cisplatin, Humans, Kidney, Biomarkers, Apoptosis, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review